Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA H1047R |
| Therapy | Inavolisib |
| Indication/Tumor Type | colon cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA H1047R | colon cancer | sensitive | Inavolisib | Preclinical - Cell culture | Actionable | In a preclinical study, Itovebi (inavolisib) treatment led to decreased cell viability in a colon cancer cell line expressing PIK3CA H1047R in culture (PMID: 34544753). | 34544753 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34544753) | RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy. | Full reference... |